Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
Jer-Hwa Chang,
Jeng-Fong Chiou,
Ching-Sheng Hung,
Ming-Che Liu,
Hui-Wen Chang,
Shiao-Ya Hong,
Cheng-Yi Wang,
Yi-Ling Lin,
Yi-Chen Hsieh,
Chi-Li Chung,
Ying-Shih Su,
Shu-Tai Shen Hsiao,
Doresses Liu,
Jian-Jong Liang,
Chun-Che Liao,
Chih-Shin Chang,
Kevin Shu-Leung Lai,
Han-Chuan Chuang,
Ko-Ling Chien,
Wei-Ciao Wu,
Yuan-Chii G. Lee,
Sey-En Lin,
Yung-Kang Shen,
Chiung-Fang Hsu,
Jude Chu-Chun Wang,
Shih-Hsin Hsiao
Affiliations
Jer-Hwa Chang
School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
Jeng-Fong Chiou
Department of Radiation Oncology, Taipei Medical University Hospital, Taipei 11031, Taiwan
Ching-Sheng Hung
School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
Ming-Che Liu
Department of Urology, Taipei Medical University Hospital, Taipei 11031, Taiwan
Hui-Wen Chang
School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
Shiao-Ya Hong
Medical Research Center, Cardinal Tien Hospital, New Taipei 24148, Taiwan
Cheng-Yi Wang
Department of Internal Medicine, Cardinal Tien Hospital, New Taipei 23148, Taiwan
Yi-Ling Lin
Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan
Yi-Chen Hsieh
Ph.D. Program of Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
Chi-Li Chung
Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
Ying-Shih Su
Division of Infectious Disease, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan
Shu-Tai Shen Hsiao
Department of Nursing, Taipei Medical University Hospital, Taipei 11031, Taiwan
Doresses Liu
Department of Nursing, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan
Jian-Jong Liang
Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan
Chun-Che Liao
Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan
Chih-Shin Chang
Biomedical Translation Research Center, Academia Sinica, Taipei 11529, Taiwan
Kevin Shu-Leung Lai
Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 11031, Taiwan
Han-Chuan Chuang
Division of Infectious Disease, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan
Ko-Ling Chien
Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 11031, Taiwan
Wei-Ciao Wu
Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
Yuan-Chii G. Lee
Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
Sey-En Lin
Department of Anatomic Pathology, New Taipei Municipal TuCheng Hospital, Chang Gung Memorial Foundation, New Taipei 23652, Taiwan
Yung-Kang Shen
School of Dental Technology, College of Oral Medicine, Taipei Medical University, Taipei 11031, Taiwan
Chiung-Fang Hsu
Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 11031, Taiwan
Jude Chu-Chun Wang
Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 11031, Taiwan
Shih-Hsin Hsiao
Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
Background: The ChAdOx1 nCoV-19 vaccine has been widely administered against SARS-CoV-2 infection; however, data regarding its immunogenicity, reactogenicity, and potential differences in responses among Asian populations remain scarce. Methods: 270 participants without prior COVID-19 were enrolled to receive ChAdOx1 nCoV-19 vaccination with a prime–boost interval of 8–9 weeks. Their specific SARS-CoV-2 antibodies, neutralizing antibody titers (NT50), platelet counts, and D-dimer levels were analyzed before and after vaccination. Results: The seroconversion rates of anti-RBD and anti-spike IgG at day 28 after a boost vaccination (BD28) were 100% and 95.19%, respectively. Anti-RBD and anti-spike IgG levels were highly correlated (r = 0.7891), which were 172.9 ± 170.4 and 179.3 ± 76.88 BAU/mL at BD28, respectively. The geometric mean concentrations (GMCs) of NT50 for all participants increased to 132.9 IU/mL (95% CI 120.0–147.1) at BD28 and were highly correlated with anti-RBD and anti-spike IgG levels (r = 0.8248 and 0.7474, respectively). Body weight index was statistically significantly associated with anti-RBD IgG levels (p = 0.035), while female recipients had higher anti-spike IgG levels (p = 0.038). The GMCs of NT50 declined with age (p = 0.0163) and were significantly different across age groups (159.7 IU/mL for 20–29 years, 99.4 IU/mL for ≥50 years, p = 0.0026). Injection-site pain, fever, and fatigue were the major reactogenicity, which were more pronounced after prime vaccination and in younger participants (<50 years). Platelet counts decreased and D-dimer levels increased after vaccination but were not clinically relevant. No serious adverse events or deaths were observed. Conclusion: The vaccine is well-tolerated and elicited robust humoral immunity against SARS-CoV-2 after standard prime–boost vaccination in Taiwanese recipients.
